ENANTA PHARMACEUTICALS ($NASDAQ:ENTA) released their third quarter fiscal year 2023 earnings results on June 30 2023. Their total revenue for the quarter was USD 18.9 million, a 3.0% drop from the same period last year. Additionally, their net income decreased to USD -39.1 million from -31.7 million in the previous year.
The stock opened at $19.8 and closed at $19.3, closing down 2.4% from its prior closing price of $19.8. This marks a significant drop in the stock price, raising questions within the market about the company’s financial performance. The company’s primary focus is to discover and develop drugs that target HBV replication and have a higher efficacy and safety profile than existing treatments.
However, this quarter’s performance has failed to meet expectations and investors are concerned about the company’s ability to maintain its momentum. Overall, investors remain cautious about the future of ENANTA PHARMACEUTICALS and its stock price in the near term. With the release of its third quarter earnings results, it is clear that the company is facing a challenging environment and must focus on continuing to innovate and deliver value to shareholders. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Enanta Pharmaceuticals. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Enanta Pharmaceuticals. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Enanta Pharmaceuticals. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Enanta Pharmaceuticals are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we recently conducted an analysis of ENANTA PHARMACEUTICALS‘s wellbeing. Our analysis yielded a Risk Rating, indicating that ENANTA PHARMACEUTICALS is a high risk investment in terms of both its financial and business aspects. We detected 4 risk warnings in ENANTA PHARMACEUTICALS’ balance sheet, cashflow statement, non financial, and financial journal. If you’re looking to gain more insight on this matter, we invite you to register on goodwhale.com to take a closer look at our findings. Doing so will help you make more informed decisions when it comes to ENANTA PHARMACEUTICALS’s investments. More…
Risk Rating Analysis
Star Chart Analysis
Its main competitors are WPD Pharmaceuticals Inc, Nabriva Therapeutics PLC, SILO Pharma Inc.
– WPD Pharmaceuticals Inc ($OTCPK:WPDPF)
WPD Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics for the treatment of cancer and other diseases. The company’s market cap is $22.69 million and its ROE is -345.33%. WPD Pharmaceuticals Inc. is headquartered in Toronto, Canada.
– Nabriva Therapeutics PLC ($NASDAQ:NBRV)
Nabriva Therapeutics PLC is a clinical-stage biopharmaceutical company engaged in the research and development of anti-infective agents to treat serious and life-threatening infections. The company’s lead product candidate, lefamulin, is a semi-synthetic pleuromutilin antibiotic for intravenous and oral administration in development for the community-acquired bacterial pneumonia. Nabriva Therapeutics PLC has a market cap of 6.26M as of 2022, a Return on Equity of -72.24%. The company’s focus on developing novel anti-infectives agents makes it a unique player in the market, and its market cap and ROE reflect this.
Investors should take note of Enanta Pharmaceuticals’ recent financial results. For the third quarter of 2023, the company reported total revenue of USD 18.9 million, a decrease of 3.0% compared to the same period last year. Net income for the quarter was reported at USD -39.1 million, a decline from the previous year’s figure of -31.7 million. This signifies a deterioration in the company’s financial performance, and investors should exercise caution when considering this stock.